Assessing the effectiveness of Interleukin-2 therapy in experimental type 1 diabetes.

In conclusion, further decreasing IL-2 dosage may not be a suitable approach for T1D therapy, and the limited success suggests that an alternative low dose IL-2 therapy strategy or other immunotherapies should be considered.